GLP-1 research questions — bring your protocol confusions and shared experiences

Kicking off this discussion thread for ongoing community input on GLP-1 peptide research questions. This category has the deepest published research on the platform but the community discussion can lag behind the research literature, especially for newer compounds. Rather than wait for an active community to materialize, I want to seed this thread with specific questions and experience-types that lurkers can use as onramps. Reply with your own questions or respond to anyone else's — the goal is durable Q&A that helps the next person who lands on this thread via search.

Specific questions or experiences worth sharing.

Dose titration experiences. If you have run a research protocol with semaglutide, tirzepatide, or retatrutide, what did the titration schedule look like? Did the protocol follow the published 4-week-per-step pattern, or was it adjusted? What gastrointestinal effects appeared at which dose, and at what point did they resolve? Specific data is more useful than general claims — "subjects in the protocol moved from 0.25mg to 0.5mg at week 4 and reported moderate nausea for the first 5 days" is far more useful than "titration was hard."

Lean mass preservation strategies. If body composition was tracked during GLP-1 research with DEXA, BIA, or even just bodyweight plus measurements, what protein intake and resistance training pattern was used? What did the lean mass numbers look like at the start versus end of the protocol? The published research suggests roughly 25-40% of weight lost tends to be lean mass without intervention; what worked to push that number lower in your specific case?

Cagrilintide combination experiences. The semaglutide + cagrilintide combination is showing strong outcomes in published research but community-level experience reports are still thin. If a protocol added cagrilintide to a semaglutide regimen, when was it added, at what dose, and what changed? What did the side effect profile look like compared to semaglutide alone?

Plateau and tapering questions. The 5-7 day half-life of these compounds means tapering off is gradual whether intended or not. If a protocol stopped and the rebound metrics were tracked over the following weeks, what did the timeline look like? How long did appetite suppression persist after the last dose?

Vendor-specific quality reports. If multiple vendors were used for the same compound and differences in apparent potency or side effect profile were observed, that is data the community can use. Specific vendor names and what was observed is more useful than vague "quality varies" claims.

A note on framing.
This category has the highest cross-traffic with mainstream weight-loss conversations, and that means a lot of newcomers land on these threads expecting consumer-product framing. Please keep responses research-framed — describe what was observed in the research context, not what someone "should do" or what "you should expect." The platform's legal posture and the long-term durability of this content depend on that discipline.

If you have questions but do not want to post them publicly, DMs are open. The thread is the right place for shareable Q&A but private messages work for everything else.